0.6689
price up icon10.49%   0.0635
after-market After Hours: .68 0.0111 +1.66%
loading
Ovid Therapeutics Inc stock is traded at $0.6689, with a volume of 1.77M. It is up +10.49% in the last 24 hours and up +115.50% over the past month. Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$0.6054
Open:
$0.658
24h Volume:
1.77M
Relative Volume:
1.31
Market Cap:
$47.57M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-0.8919
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
+81.77%
1M Performance:
+115.50%
6M Performance:
-4.85%
1Y Performance:
-35.06%
1-Day Range:
Value
$0.594
$0.6695
1-Week Range:
Value
$0.36
$0.6695
52-Week Range:
Value
$0.2425
$1.47

Ovid Therapeutics Inc Stock (OVID) Company Profile

Name
Name
Ovid Therapeutics Inc
Name
Phone
212-776-4381
Name
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Name
Employee
23
Name
Twitter
@OvidRx
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
OVID's Discussions on Twitter

Compare OVID with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
OVID
Ovid Therapeutics Inc
0.6689 26.17M 391.70K -52.34M -45.92M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-18-24 Downgrade Oppenheimer Outperform → Perform
Apr-30-24 Initiated B. Riley Securities Buy
Apr-29-24 Initiated H.C. Wainwright Buy
Apr-05-24 Initiated Wedbush Outperform
Dec-21-23 Initiated BTIG Research Buy
Oct-13-23 Initiated Oppenheimer Outperform
Apr-20-21 Downgrade Cantor Fitzgerald Buy → Neutral
Mar-03-21 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-02-20 Downgrade Citigroup Buy → Neutral
Dec-02-20 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-04-19 Initiated RBC Capital Mkts Outperform
Apr-20-18 Initiated Ladenburg Thalmann Buy
View All

Ovid Therapeutics Inc Stock (OVID) Latest News

pulisher
Jul 22, 2025

Is Ovid Therapeutics Inc. a good long term investmentRapid wealth multiplication - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

July 2025's Top Penny Stocks To Watch - simplywall.st

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Ovid Therapeutics Inc. stock priceFree Capital Growth Strategies - printweek.in

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Ovid Therapeutics Inc. stockPhenomenal returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Ovid Therapeutics Stock Soars 13.88% on Investor Optimism - AInvest

Jul 22, 2025
pulisher
Jul 20, 2025

Ovid Therapeutics Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional

Jul 20, 2025
pulisher
Jul 19, 2025

Ovid Therapeutics (NASDAQ:OVID) Receives Average Rating of “Buy” from Analysts - Defense World

Jul 19, 2025
pulisher
Jul 19, 2025

Ovid Therapeutics (NASDAQ:OVID) Stock Rating Upgraded by Wall Street Zen - Defense World

Jul 19, 2025
pulisher
Jul 18, 2025

What makes Ovid Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - beatles.ru

Jul 18, 2025
pulisher
Jul 17, 2025

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Jul 17, 2025
pulisher
Jul 17, 2025

Ovid Therapeutics Surges 25% Amid Analyst Hype and Strategic Pipeline Progress - AInvest

Jul 17, 2025
pulisher
Jul 15, 2025

Why Ovid Therapeutics Inc. stock attracts strong analyst attentionDaily Breakout Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Ovid Therapeutics Inc. stock performs during market volatilityTop Rated Trade Entries - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Ovid Therapeutics (NASDAQ:OVID) Stock Price Down 2% – Time to Sell? - Defense World

Jul 15, 2025
pulisher
Jul 11, 2025

Ovid Therapeutics Approves Key Proposals at Annual Meeting - The Globe and Mail

Jul 11, 2025
pulisher
Jul 10, 2025

Local Bounti (LOCL) insider files Form 144 to sell 3,500 shares - Stock Titan

Jul 10, 2025
pulisher
Jun 25, 2025

Ovid Therapeutics Sells Ganaxolone Royalties to Immedica - TipRanks

Jun 25, 2025
pulisher
Jun 17, 2025

Balance Sheet Insights: Ovid Therapeutics Inc (OVID)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX

Jun 17, 2025
pulisher
Jun 15, 2025

Stoke Therapeutics: Impressive Pipeline And Big Backers - Seeking Alpha

Jun 15, 2025
pulisher
Jun 13, 2025

Ovid Therapeutics Inc (OVID) Stock: The Story of a 52-Week Stock Range - investchronicle.com

Jun 13, 2025
pulisher
Jun 13, 2025

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier - insights.citeline.com

Jun 13, 2025
pulisher
Jun 13, 2025

Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech

Jun 13, 2025
pulisher
Jun 12, 2025

Transcript : Ovid Therapeutics Inc.Special Call - MarketScreener

Jun 12, 2025
pulisher
Jun 11, 2025

Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results - mx.advfn.com

Jun 09, 2025
pulisher
Jun 05, 2025

Ovid Therapeutics (OVID) to Showcase Biomarker Advances in Epile - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 | OVID Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Harvard Expert to Present Breakthrough Epilepsy Treatment Data at Ovid Therapeutics Event - Stock Titan

Jun 05, 2025
pulisher
Jun 01, 2025

Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Sold by BNP Paribas Financial Markets - Defense World

Jun 01, 2025
pulisher
May 30, 2025

HC Wainwright Predicts Weaker Earnings for Ovid Therapeutics - Defense World

May 30, 2025
pulisher
May 28, 2025

Ovid Therapeutics (NASDAQ:OVID) Price Target Cut to $1.50 by Analysts at HC Wainwright - Defense World

May 28, 2025
pulisher
May 28, 2025

Ovid Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 28, 2025
pulisher
May 27, 2025

Ovid Therapeutics (OVID): HC Wainwright & Co. Lowers Price Targe - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Ovid Therapeutics (OVID): Price Target Revised Amid Future Growt - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Ovid Therapeutics (OVID): Price Target Revised Amid Future Growth Prospects | OVID Stock News - GuruFocus

May 27, 2025
pulisher
May 20, 2025

Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) PT at $3.03 - Defense World

May 20, 2025

Ovid Therapeutics Inc Stock (OVID) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Cap:     |  Volume (24h):